Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells.
about
Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinaseManufactured and airborne nanoparticle cardiopulmonary interactions: a review of mechanisms and the possible contribution of mast cellsSubstance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension.Increased myocardial stiffness due to cardiac titin isoform switching in a mouse model of volume overload limits eccentric remodelingThe emerging prominence of the cardiac mast cell as a potent mediator of adverse myocardial remodelingSubstance P in heart failure: the good and the bad.Substance P induces cardioprotection in ischemia-reperfusion via activation of AKT.New frontiers in heart hypertrophy during pregnancy.Mast cells in human and experimental cardiometabolic diseases.The role of neuropeptides in adverse myocardial remodeling and heart failure.Molecular and cellular neurocardiology: development, and cellular and molecular adaptations to heart disease.Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer ChemoresistanceSubstance P receptor antagonism: a potential novel treatment option for viral-myocarditisType 2 diabetes impairs tendon repair after injury in a rat model.Differential expression of the angiotensin-(1-12)/chymase axis in human atrial tissue.The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension
P2860
Q26998447-10E4C757-B99C-486A-80AF-9A8567075E50Q28388340-0E25CB3F-1623-44FC-A15B-A4439B92786CQ33705797-EB1CFD88-E515-4CBA-868F-59C3B1F40726Q34995889-C79BCE38-A99A-4BDB-AB7E-5922B555F9CDQ35578675-2141EF62-39AC-4C26-9A86-E8A041600662Q35670008-32103828-F556-4D2B-81D0-3EBEE2AE5599Q35958631-7FFD5F92-14AC-4B39-A050-74FDD8307513Q36190273-86922F9E-4BC6-4E10-9D80-652D06374297Q38563903-A3BE7082-16F3-4FE3-8795-7E5D829727B6Q39093111-5D31D44E-D47D-4843-A314-FAE798033D5BQ40722220-030BDC3A-2983-401D-9F3D-1B09FFE1485EQ40753692-1810D6C3-04B4-4FB2-9C8F-3A4D9850A8F9Q41371705-43C59792-7498-4A3C-8DC2-A684A638238BQ43596460-B574B718-2570-460C-891E-83A77CDCC07FQ48080337-4C1FF3C9-CB80-4356-8B5E-82CB4017611BQ57167791-7F7B3EB3-0B2F-4644-A491-9AF7900E9D1E
P2860
Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Substance P induces adverse my ...... involving cardiac mast cells.
@ast
Substance P induces adverse my ...... involving cardiac mast cells.
@en
type
label
Substance P induces adverse my ...... involving cardiac mast cells.
@ast
Substance P induces adverse my ...... involving cardiac mast cells.
@en
prefLabel
Substance P induces adverse my ...... involving cardiac mast cells.
@ast
Substance P induces adverse my ...... involving cardiac mast cells.
@en
P2093
P2860
P356
P1476
Substance P induces adverse my ...... involving cardiac mast cells.
@en
P2093
Brittany A Law
Giselle C Meléndez
Jianping Li
Joseph S Janicki
Scott C Supowit
P2860
P304
P356
10.1093/CVR/CVR244
P50
P577
2011-09-09T00:00:00Z